PHARMA MONITOR

Strategic Insights on Pharma Trends

Corporate Monitor

Brand Monitor
Evolution Index, i.e. EI

In the pharmaceutical industry, the Evolution Index is a crucial tool for strategic decision-making. It
measures a product's growth relative to its market, offering valuable insights for maximizing
profitability and navigating market competition effectively. With a range from-100 to positive values,
this index enables companies to make informed, flexible decisions and stay ahead in a competitive
landscape.

Analyzing the evolution index over time in combination with the current sales gives us clear picture
how the company products are competing on the market against the total market sales.

100 + (Brand Growth%) x 100)

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
 Therapy Monitor

Therapy Monitor
 Therapy Monitor In the Month of May 25, Cardiac segment led growth both in absolute value
(₹292.7 Cr) and percentage terms (11.7% YoY), driven by India's escalating
chronic disease burden and continued uptake of antihypertensives and lipid-
MTH May 25 lowering therapies. Cardiovascular diseases (CVDs) now account for 26–27% of
all deaths in India; with Indians experiencing heart disease 5–10 years earlier
SUPER GROUP VAL % Gr % Contri EI Incr Gain than the global average. The age-standardized CVD death rate in India (272 per
100,000) surpasses the global average (235 per 100,000) as per a report
IPM 19719.8 7.2% 1330.0 published in Circulation journal. Rising prevalence of hypertension, obesity, poor
CARDIAC 2802.1 11.7% 14.21% 104% 292.7 diet, sedentary lifestyles, smoking, and pollution continues to compound the
GASTRO INTESTINAL 2503.3 5.1% 12.69% 98% 121.9
burden across both urban and rural populations.
ANTI-INFECTIVES 2129.7 7.6% 10.80% 100% 150.7
ANTI DIABETIC 1842.3 6.7% 9.34% 100% 115.9
VITAMINS / MINERALS / NUTRIENTS 1818.8 4.8% 9.22% 98% 83.5 India also ranks as the second-highest diabetic population globally, with an
PAIN / ANALGESICS 1364.4 7.2% 6.92% 100% 91.7 estimated 74 million people affected as of 2024, projected to exceed 100 million
NEURO / CNS 1340.1 7.7% 6.80% 100% 95.4 by 2035. The Anti-Diabetic therapy segment grew a healthy 6.7%, but the real
DERMA 1252.7 5.2% 6.35% 98% 62.1 momentum came from non-insulin injectables, particularly tirzepatide (Mounjaro)
RESPIRATORY 1228.7 7.8% 6.23% 101% 88.8 and semaglutide (Rybelsus). Eli Lilly’s Mounjaro, a dual GIP/GLP-1 receptor
GYNAECOLOGICAL 636.3 0.1% 3.23% 93% 0.8 agonist, has reshaped Type 2 diabetes management, offering superior HbA1c
BLOOD RELATED 635.2 8.1% 3.22% 101% 47.7 control and significant weight loss, as demonstrated in the SURPASS trials,
ANTI-NEOPLASTICS 483.0 11.7% 2.45% 104% 50.5 even outperforming GLP-1 agonists like semaglutide. Its India launch in early
OPHTHAL / OTOLOGICALS 380.6 3.0% 1.93% 96% 11.2
2025 has generated strong prescriber interest and adoption, especially in urban
UROLOGY 337.2 12.3% 1.71% 105% 36.9
HORMONES 315.5 7.6% 1.60% 100% 22.4
metabolic clinics.
VACCINES 188.1 10.7% 0.95% 103% 18.1
OTHERS 169.3 13.4% 0.86% 106% 20.0 Anti-Malarials despite their relatively smaller base, posted the highest growth
STOMATOLOGICALS 134.8 10.0% 0.68% 103% 12.3 rates at 15.2%. As per the WHO 2022 report, India contributes to ~66% of
SEX STIMULANTS / REJUVENATORS 108.6 0.6% 0.55% 94% 0.7 malaria cases in the South-East Asia region. The spike in anti-malarial sales
ANTI MALARIALS 49.2 15.2% 0.25% 107% 6.5 during May 2025 may reflect seasonal transmission uptick and stockpiling
ahead of the monsoon, in line with historical patterns of increased vector-borne
infections during this period.

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
Corporate Monitor
 Corporate Monitor #1 to 20
Several top corporates outpaced IPM growth, with Sun Pharma,
Alkem, Torrent, Dr. Reddy’s, and IPCA registering strong double-digit
G/L
Rank CORPORATE VAL % Gr % MS
%MS
EI Incr Gain momentum.
Sun Pharma led the IPM with robust growth in Neurology, driven by
IPM 19719.8 7.2% 100.00% 100% 1330.0
antidepressants (Escitalopram + Clonazepam), antiepileptics
1 SUN* 1661.5 11.2% 8.43% 104% 167.5
2 ABBOTT* 1133.7 6.5% 5.75% 99% 69.3
(Oxcarbazepine), atypical antipsychotics (Quetiapine, Olanzapine),
3 MANKIND* 1119.0 8.6% 5.67% 101% 88.8 and anti-parkinsonian drugs (Levodopa + Carbidopa, Pramipexole).
4 CIPLA 980.0 7.9% 4.97% 101% 71.5 Alkem delivered double-digit growth across anti-infectives
5 ALKEM* 795.2 10.3% 4.03% 103% 74.5 (Amoxycillin + Clavulanic acid, Cefixime, Piperacillin + Tazobactam),
6 INTAS 754.3 9.4% 3.83% 102% 64.7 gastro (Pantoprazole, Domperidone combos), vitamins
7 TORRENT 737.2 10.8% 3.74% 103% 72.0
(Cholecalciferol), and pain/analgesics (Paracetamol, Diclofenac +
8 LUPIN 714.2 7.7% 3.62% 100% 51.0
9 ZYDUS* 649.3 5.9% 3.29% 99% 36.0
Paracetamol + Serratiopeptidase, Nimesulide combos).
10 DR. REDDYS 604.4 11.2% 3.06% 104% 60.8 Torrent Pharma continued strong performance in cardiac (Nebivolol,
11 MACLEODS 590.9 7.7% 3.00% 100% 42.3 Rosuvastatin + Aspirin, Nicorandil), gastro (Domperidone +
12 ARISTO 528.3 4.8% 2.68% 98% 24.4 Esomeprazole), and neurology (Lacosamide, Pregabalin, Sertraline).
13 EMCURE* 511.0 6.0% 2.59% 99% 28.9 Dr. Reddy’s grew through GI (Omeprazole, Domperidone +
14 GLENMARK 417.4 8.7% 2.12% 101% 33.2 Esomeprazole, Saccharomyces Boulardii), derma (Emollients,
15 USV 405.8 6.1% 2.06% 99% 23.4
Glycerin + Pramoxine, Minoxidil), anti-allergics (Hydroxyzine,
16 GSK 375.3 1.2% 1.90% 94% 4.3
17 IPCA 372.4 10.8% 1.89% 103% 36.3 Levocetirizine), and respiratory products (Bromhexine +
18 MICRO 296.5 2.6% 1.50% 96% 7.6 Dextromethorphan combos).
19 ERIS LS 276.9 6.8% 1.40% 100% 17.7 IPCA saw strong gains in pain (Aceclofenac + Paracetamol +
20 PFIZER* 259.9 0.5% 1.32% 94% 1.2 Serratiopeptidase), cardiac (Telmisartan + Chlorthalidone), diuretics
(Chlorthalidone), and anti-malarials (Hydroxychloroquine).

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
 Corporate Monitor #21 to 40
G/L
Rank CORPORATE VAL % Gr % MS EI Incr Gain
%MS
IPM 19719.8 7.2% 100.00% 100% 1330.0 Several mid-ranked corporates posted stellar double-digit growth, led
21 ALEMBIC 229.2 1.1% 1.16% 94% 2.6 by JB Chemicals, La Renon, Corona, Nutricia International, Bayer,
22 JB CHEMICALS 220.4 10.7% 1.12% 103% 21.4 and AstraZeneca.
23 FDC 200.5 5.5% 1.02% 98% 10.4 JB Chemicals drove growth through cardiac therapies, notably
24 SANOFI INDIA 172.1 3.2% 0.87% 96% 5.3
Cilnidipine, Cilnidipine + Telmisartan, and Nifedipine.
25 AJANTA 153.0 6.8% 0.78% 100% 9.8
26 LA RENON 151.9 10.5% 0.77% 103% 14.5 La Renon continued strong momentum in nutraceuticals (S-Adenosyl
27 HIMALAYA 148.7 5.4% 0.75% 98% 7.6 Methionine), neuro/CNS, and anti-diabetic OAD combos like
28 CORONA 129.3 11.5% 0.66% 104% 13.4 Dapagliflozin + Sitagliptin.
29 PROCTER AND GAMBLE HEALTH 118.7 9.3% 0.60% 102% 10.1 Corona Remedies saw gains from gynecology (Dydrogesterone) and
30 FRANCO 110.6 6.5% 0.56% 99% 6.7 OAD-based anti-diabetic combos (Glimepiride + Metformin).
31 Nutricia International Pvt.Ltd 107.6 17.7% 0.55% 110% 16.2
Nutricia International posted robust growth driven by its infant
32 CADILA 105.0 -8.4% 0.53% 85% -9.7
33 INDOCO 104.9 5.2% 0.53% 98% 5.2
formula-based nutraceuticals portfolio.
34 BAYER 103.6 14.0% 0.53% 106% 12.7 Bayer expanded through cardiac (Finerenone) and gynecology
35 SYSTOPIC 100.7 7.1% 0.51% 100% 6.7 (Estradiol) segments.
36 HETERO 98.0 4.2% 0.50% 97% 4.0 AstraZeneca ensured growth via platelet aggregation inhibitors
37 BLUE CROSS 97.2 5.1% 0.49% 98% 4.7 (Ticagrelor) in cardiac and Dapagliflozin in anti-diabetics.
38 MEDLEY 95.3 3.5% 0.48% 96% 3.2
39 FOURRTS 88.8 6.8% 0.45% 100% 5.7
40 ASTRAZENECA 87.7 11.4% 0.44% 104% 9.0

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
 Corporate Monitor #41 to 60
G/L
Rank CORPORATE VAL % Gr % MS EI Incr Gain
%MS
IPM 19719.8 7.2% 100.00% 100% 1330.0 Among 41 to 60 rank, Several companies outpaced IPM growth, with
41 HEGDE & HEGDE 86.9 7.9% 0.44% 101% 6.3 Meyer, Apex, Pharmed, Samarth, and Reliance posting double-digit
42 APEX 84.5 13.8% 0.43% 106% 10.2 growth, while Hegde & Hegde also outperformed the IPM.
43 WIN-MEDICARE 77.2 0.9% 0.39% 94% 0.7 Apex grew through Vitamins/Minerals/Nutrients (Zincovit) and Pain
44 MEYER 74.8 11.7% 0.38% 104% 7.8
Analgesics (Paracetamol).
45 JANSSEN 70.6 1.2% 0.36% 94% 0.9
46 WALLACE 68.4 4.7% 0.35% 98% 3.1 Meyer delivered strong growth from Calcium + Cholecalciferol
47 PHARMED 67.0 16.9% 0.34% 109% 9.7 combos (Calcimax P), musculoskeletal products (e.g., collagen),
48 RAPTAKOS 64.1 1.8% 0.33% 95% 1.1 Thiocholchicoside + Aceclofenac + Paracetamol, and antiflatulents
49 NOVARTIS* 61.5 1.2% 0.31% 94% 0.7 like Dill Oil + Fennel Oil + Simethicone.
50 BOEHRINGER INGELHEIM 59.4 -2.4% 0.30% 91% -1.5 Pharmed grew via Calcium + Cholecalciferol and Osteoarthritis
51 SAMARTH 58.7 16.6% 0.30% 109% 8.4
therapies (e.g., Ascorbic acid + Chondroitin + Collagen +
52 MSD* 57.1 0.0% 0.29% 93% 0.0
53 VIATRIS 53.7 6.0% 0.27% 99% 3.0
Hyaluronic acid).
54 RELIANCE 51.1 37.5% 0.26% 128% 13.9 Samarth performed well in Cardiac (Unfractionated Heparins) and
55 ALLERGAN 50.4 4.1% 0.26% 97% 2.0 Anti-infectives (Polymyxin B).
56 AKUMENTIS 48.1 3.8% 0.24% 97% 1.7 Reliance continued momentum through blood-related products,
57 WOCKHARDT 47.4 3.7% 0.24% 97% 1.7 including whole blood and plasma substitutes (Albumin).
58 TROIKAA 47.2 -3.2% 0.24% 90% -1.6
59 KLM 45.4 3.3% 0.23% 96% 1.4
60 RPG 44.2 3.2% 0.22% 96% 1.4

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
 Corporate Monitor #61 to 80
G/L
Rank CORPORATE VAL % Gr % MS EI Incr Gain
%MS
Merck, Roche, Pure & Cure, Unison, Natco, Lloyd HC, and Ozone
IPM 19719.8 7.2% 100.00% 100% 1330.0
recorded double-digit growth.
61 MANEESH* 43.8 4.1% 0.22% 97% 1.7
62 SERDIA 43.4 3.0% 0.22% 96% 1.3
Merck saw continued success in Cardiac therapy, led by Amlodipine
63 MSN 42.7 4.9% 0.22% 98% 2.0 + Bisoprolol (anti-hypertensive).
64 WALTER BUSHNELL 42.3 4.8% 0.21% 98% 1.9 Roche achieved strong growth in Anti-neoplastics, particularly
65 BIOLOGICAL E 41.5 -6.5% 0.21% 87% -2.9 through monoclonal antibodies (Pertuzumab + Trastuzumab,
66 CENTAUR 41.3 3.9% 0.21% 97% 1.6 Atezolizumab).
67 MERCK 40.3 10.3% 0.20% 103% 3.8
Pure & Cure Healthcare gained in the Cardiac segment, driven by
68 ROCHE 40.0 35.7% 0.20% 127% 10.5
69 SERUM INSTITUTE 39.9 5.0% 0.20% 98% 1.9
lipid-lowering combinations: Aspirin + Rosuvastatin + Clopidogrel.
70 PURE AND CURE HEALTHCARE 38.0 23.8% 0.19% 115% 7.3 Unison benefited from its Atenolol + Amlodipine combination in
71 UNISON 37.2 29.0% 0.19% 120% 8.4 Cardiac.
72 GALDERMA 36.6 4.9% 0.19% 98% 1.7 Natco continued its upward trajectory in Oncology with Protein
73 INTEGRACE HEALTH 35.7 -4.4% 0.18% 89% -1.6 Kinase Inhibitors like Imatinib mesylate.
74 JOHNSON & JOHNSON 33.1 7.3% 0.17% 100% 2.3 Lloyd HC performed well due to Cilnidipine-based
75 NATCO 33.0 12.4% 0.17% 105% 3.6
antihypertensives.
76 ALBERT DAVID 32.7 2.0% 0.17% 95% 0.6
77 TABLETS INDIA 32.2 6.3% 0.16% 99% 1.9 Ozone grew through its Anti-diabetic segment, particularly OAD
78 PIRAMAL 32.0 4.5% 0.16% 97% 1.4 combinations like Voglibose + Metformin + Glimepiride.
79 LLOYD HC 31.9 26.0% 0.16% 118% 6.6
80 OZONE 31.8 22.6% 0.16% 114% 5.9

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
 Corporate Monitor #81 to 100
Overseas, Entod, BMS, Gufic, Eli Lilly, Kepler HC, Charak, UNS, and
G/L
Rank CORPORATE VAL % Gr % MS
%MS
EI Incr Gain Galpha posted double-digit growth.
Overseas showed robust growth across
IPM 19719.8 7.2% 100.00% 100% 1330.0
Vitamins/Minerals/Nutrients (e.g., Calcium + Calcitriol) and
81 OVERSEAS 30.4 18.0% 0.15% 110% 4.6
82 ENTOD 30.0 11.5% 0.15% 104% 3.1
Gastrointestinal therapy (notably anti-spasmodics like Drotaverine).
83 NEON 29.5 -9.9% 0.15% 84% -3.3 Entod contributed steadily (note: specifics not given in image, but
84 BMS 28.8 16.0% 0.15% 108% 4.0 often driven by ophthalmology or dermatology segments).
85 GUFIC BIOSCIENCE 27.4 12.1% 0.14% 105% 3.0 BMS (Bristol-Myers Squibb) surged due to monoclonal antibodies in
86 FRESENIUS 27.2 1.8% 0.14% 95% 0.5 the Oncology space, especially Nivolumab.
87 ELI LILLY 27.0 61.8% 0.14% 151% 10.3
Gufic Bioscience experienced strong momentum in Anti-infectives,
88 LEEFORD HC 27.0 4.6% 0.14% 98% 1.2
89 EAST INDIA 26.8 4.1% 0.14% 97% 1.0
powered by antibacterials like Meropenem.
90 KEPLER HC 26.3 13.4% 0.13% 106% 3.1 Eli Lilly saw exceptional gains in Anti-diabetics, led by non-insulin
91 CHARAK 26.2 23.1% 0.13% 115% 4.9 injectables like Tirzepatide.
92 LINCOLN 25.9 8.8% 0.13% 101% 2.1 Kepler HC performed well in Vitamins, particularly through
93 MED MANOR 25.5 9.0% 0.13% 102% 2.1 combinations like L-Methylfolate + Methylcobalamin + Pyridoxine.
94 JAGSONPAL 24.6 -2.7% 0.12% 91% -0.7 Charak posted growth in Gynecology and Gastrointestinal therapies,
95 UNS 24.5 12.8% 0.12% 105% 2.8
including Ayurvedic hepatoprotectives.
96 LINUX LAB. 23.2 8.0% 0.12% 101% 1.7
97 ICON LSS 23.1 4.6% 0.12% 98% 1.0 UNS gained from its Cardiac offerings, especially Ubidecarenone
98 Aurobindo Pharmaceuticals Ltd. 22.6 -4.0% 0.11% 90% -0.9 (Coenzyme Q10).
99 MODI MUNDI 22.2 -9.4% 0.11% 85% -2.3 Galpha showed good performance in Antibacterials, driven by
100 GALPHA 21.2 11.4% 0.11% 104% 2.2 Ceftriaxone + Sulbactam combinations.

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
Brand Monitor
 Brand Monitor #1 to 20
% MS in G/L % EI against
Incr Gain
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR IPM MS in SG
IPM 19719.8 7.2% 100% 1330.0
1 USV USV PVT LTD GLYCOMET GP ANTI DIABETIC 7% 73.7 5.5% 0.37% 99% 3.9
2 ALKEM* ALKEM LABORATORIES LTD. PAN GASTRO INTESTINAL 5% 69.6 10.2% 0.35% 105% 6.4
3 HIMALAYA HIMALAYA DRUG COMPANY LIV.52 GASTRO INTESTINAL 5% 68.9 17.1% 0.35% 111% 10.0
4 ABBOTT* NOVO NORDISK INDIA PVT LTD MIXTARD ANTI DIABETIC 7% 65.7 -0.5% 0.33% 93% -0.3
5 ALKEM* ALKEM LABORATORIES LTD. PAN D GASTRO INTESTINAL 5% 60.3 13.2% 0.31% 108% 7.0
6 FDC FDC LTD. ELECTRAL GASTRO INTESTINAL 5% 59.5 1.0% 0.30% 96% 0.6
7 CIPLA CIPLA LTD. FORACORT RESPIRATORY 8% 58.0 0.3% 0.29% 93% 0.2
8 ABBOTT* ABBOTT INDIA LTD. UDILIV GASTRO INTESTINAL 5% 54.8 5.3% 0.28% 100% 2.8
9 IPCA IPCA LABORATORIES PVT LTD. ZERODOL SP PAIN / ANALGESICS 7% 53.1 12.1% 0.27% 105% 5.8
10 ABBOTT* ABBOTT INDIA LTD. THYRONORM HORMONES 8% 52.3 18.5% 0.27% 110% 8.2
11 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MONOCEF ANTI-INFECTIVES 8% 52.1 -0.8% 0.26% 92% -0.4
12 GSK GLAXOSMITHKLINE PHARMACEUTICALS LTD. AUGMENTIN ANTI-INFECTIVES 8% 51.9 -1.8% 0.26% 91% -1.0
13 ALKEM* ALKEM LABORATORIES LTD. CLAVAM ANTI-INFECTIVES 8% 51.8 16.9% 0.26% 109% 7.5
14 JB CHEMICALS JB CHEMICALS CILACAR CARDIAC 12% 50.0 18.1% 0.25% 106% 7.7
15 GLENMARK GLENMARK PHARMACEUTICALS LTD. TELMA CARDIAC 12% 47.1 12.0% 0.24% 100% 5.0
16 ABBOTT* NOVO NORDISK INDIA PVT LTD RYZODEG ANTI DIABETIC 7% 45.5 9.2% 0.23% 102% 3.8
17 WIN-MEDICARE WIN-MEDICARE PVT. LTD. BETADINE DERMA 5% 45.1 2.2% 0.23% 97% 1.0
18 JANSSEN JANSSEN ULTRACET PAIN / ANALGESICS 7% 44.6 2.9% 0.23% 96% 1.3
19 FRANCO FRANCO INDIAN PHARMACEUTICALS PVT LTD DEXORANGE BLOOD RELATED 8% 43.1 0.3% 0.22% 93% 0.1
20 MANKIND* MANKIND PHARMACEUTICALS LTD. MANFORCE SEX STIMULANTS / REJUVENATORS 1% 42.5 -3.4% 0.22% 96% -1.5

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
 Brand Monitor #21 to 40
% MS in G/L % EI against
Incr Gain
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR IPM MS in SG
IPM 19719.8 7.2% 100% 1330.0
21 APEX APEX LABORATORIES LTD. ZINCOVIT VITAMINS / MINERALS / NUTRIENTS 5% 41.7 7.0% 0.21% 102% 2.7
22 USV USV PVT LTD ECOSPRIN AV CARDIAC 12% 40.3 7.4% 0.20% 96% 2.8
23 SUN* SUN PHARMA LABORATORIES LTD. LEVIPIL NEURO / CNS 8% 39.8 4.0% 0.20% 97% 1.5
24 ARISTO ARISTO PHARMACEUTICALS PVT.LTD PANTOP GASTRO INTESTINAL 5% 38.8 4.9% 0.20% 100% 1.8
25 ASTRAZENECA ASTRAZENECA PHARMA INDIA LTD BRILINTA CARDIAC 12% 37.4 33.1% 0.19% 119% 9.3
26 SANOFI INDIA SANOFI INDIA LTD. LANTUS ANTI DIABETIC 7% 36.1 8.3% 0.18% 101% 2.8
27 SUN* RANBAXY LABORATORIES LTD ROSUVAS CARDIAC 12% 35.8 -7.8% 0.18% 83% -3.0
28 ABBOTT* ABBOTT INDIA LTD. VERTIN NEURO / CNS 8% 35.1 25.6% 0.18% 117% 7.2
29 LUPIN LUPIN LTD GLUCONORM-G ANTI DIABETIC 7% 33.2 9.8% 0.17% 103% 3.0
30 CIPLA CIPLA LTD. DUOLIN RESPIRATORY 8% 32.9 -7.7% 0.17% 86% -2.7
31 Nutricia International Pvt.Ltd NUTRICIA INTERNATIONAL PVT.LTD DEXOLAC 1 VITAMINS / MINERALS / NUTRIENTS 5% 32.6 27.5% 0.17% 122% 7.0
32 CADILA CADILA PHARMACEUTICALS LTD ACILOC GASTRO INTESTINAL 5% 32.6 -14.3% 0.17% 82% -5.4
33 PFIZER* PFIZER LTD BECOSULES VITAMINS / MINERALS / NUTRIENTS 5% 32.3 4.4% 0.16% 100% 1.4
34 ABBOTT* NOVO NORDISK INDIA PVT LTD RYBELSUS ANTI DIABETIC 7% 32.3 10.6% 0.16% 104% 3.1
35 EMCURE* ZUVENTUS HEALTHCARE LTD ZOSTUM ANTI-INFECTIVES 8% 31.9 33.8% 0.16% 124% 8.1
36 GSK GLAXOSMITHKLINE PHARMACEUTICALS LTD. BETNOVATE N DERMA 5% 31.9 7.3% 0.16% 102% 2.2
37 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MIKACIN ANTI-INFECTIVES 8% 31.6 -5.1% 0.16% 88% -1.7
38 GSK GLAXOSMITHKLINE PHARMACEUTICALS LTD. CALPOL PAIN / ANALGESICS 7% 31.5 6.5% 0.16% 99% 1.9
39 INTAS INTAS PHARMACEUTICALS LTD LEVERA NEURO / CNS 8% 30.0 12.5% 0.15% 105% 3.3
40 JB CHEMICALS JB CHEMICALS RANTAC GASTRO INTESTINAL 5% 30.0 1.5% 0.15% 97% 0.4

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
 Brand Monitor #41 to 60
% MS in G/L % EI against
Incr Gain
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR IPM MS in SG
IPM 19719.8 7.2% 100% 1330.0
41 SUN* SUN PHARMA LABORATORIES LTD. SUSTEN GYNAECOLOGICAL 0% 30.0 7.5% 0.15% 107% 2.1
42 TORRENT TORRENT PHARMACEUTICALS LTD. CHYMORAL FORTE PAIN / ANALGESICS 7% 29.4 13.3% 0.15% 106% 3.4
43 SUN* SUN PHARMA LABORATORIES LTD. GEMER ANTI DIABETIC 7% 29.3 2.6% 0.15% 96% 0.7
44 GLENMARK GLENMARK PHARMACEUTICALS LTD. CANDID DERMA 5% 29.1 19.5% 0.15% 114% 4.7
45 BMS BMS INDIA PVT. LTD. OPDYTA ANTI-NEOPLASTICS 12% 28.8 16.0% 0.15% 104% 4.0
46 Nutricia International Pvt.Ltd NUTRICIA INTERNATIONAL PVT.LTD APTAMIL GOLD VITAMINS / MINERALS / NUTRIENTS 5% 28.7 19.0% 0.15% 114% 4.6
47 IPCA IPCA LABORATORIES PVT LTD. ZERODOL P PAIN / ANALGESICS 7% 28.6 9.2% 0.15% 102% 2.4
48 ALKEM* ALKEM LABORATORIES LTD. TAXIM O ANTI-INFECTIVES 8% 28.6 21.3% 0.15% 113% 5.0
49 INTAS INTAS PHARMACEUTICALS LTD GABAPIN NT NEURO / CNS 8% 28.6 12.0% 0.14% 104% 3.1
50 FDC FDC LTD. ENERZAL GASTRO INTESTINAL 5% 28.6 5.5% 0.14% 100% 1.5
51 MICRO MICRO LABS LTD DOLO PAIN / ANALGESICS 7% 28.5 -8.4% 0.14% 85% -2.6
52 GLENMARK GLENMARK PHARMACEUTICALS LTD. TELMA AM CARDIAC 12% 28.4 4.9% 0.14% 94% 1.3
53 ALKEM* ALKEM LABORATORIES LTD. A TO Z NS VITAMINS / MINERALS / NUTRIENTS 5% 28.3 11.1% 0.14% 106% 2.8
54 ABBOTT* ABBOTT INDIA LTD. DUPHALAC GASTRO INTESTINAL 5% 27.6 7.2% 0.14% 102% 1.8
55 SUN* SUN PHARMA LABORATORIES LTD. PANTOCID GASTRO INTESTINAL 5% 27.3 2.1% 0.14% 97% 0.6
56 EMCURE* EMCURE PHARMACEUTICALS LTD OROFER-XT BLOOD RELATED 8% 27.1 -18.3% 0.14% 76% -6.1
57 MSD* MSD PHARMACEUTICALS PRIVATE LTD. JANUMET ANTI DIABETIC 7% 26.8 -1.9% 0.14% 92% -0.5
58 INTAS INTAS PHARMACEUTICALS LTD ZORYL-M ANTI DIABETIC 7% 26.6 9.2% 0.14% 102% 2.3
59 MANKIND* MANKIND PHARMACEUTICALS LTD. PREGA NEWS OTHERS 13% 26.3 24.8% 0.13% 110% 5.2
60 TORRENT TORRENT PHARMACEUTICALS LTD. SHELCAL VITAMINS / MINERALS / NUTRIENTS 5% 26.2 -6.5% 0.13% 89% -1.8

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
 Brand Monitor #61 to 80
% MS in G/L % EI against
Incr Gain
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR IPM MS in SG
IPM 19719.8 7.2% 100% 1330.0
61 GLENMARK GLENMARK PHARMACEUTICALS LTD. TELMA H CARDIAC 12% 26.2 6.3% 0.13% 95% 1.5
62 GALDERMA GALDERMA INDIA PVT. LTD CETAPHIL DERMA 5% 26.1 3.5% 0.13% 98% 0.9
63 GSK GLAXOSMITHKLINE PHARMACEUTICALS LTD. T BACT DERMA 5% 26.0 2.0% 0.13% 97% 0.5
64 ALEMBIC ALEMBIC LTD AZITHRAL ANTI-INFECTIVES 8% 25.6 -1.7% 0.13% 91% -0.4
65 CIPLA CIPLA LTD. BUDECORT RESPIRATORY 8% 25.6 -9.7% 0.13% 84% -2.7
66 CIPLA CIPLA LTD. DYTOR CARDIAC 12% 25.4 8.0% 0.13% 97% 1.9
67 SUN* RANBAXY LABORATORIES LTD VOLINI PAIN / ANALGESICS 7% 25.2 3.4% 0.13% 96% 0.8
68 RELIANCE RELIANCE LIFE SCIENCE ALBUREL BLOOD RELATED 8% 25.1 42.2% 0.13% 132% 7.5
69 ABBOTT* ABBOTT INDIA LTD. DUPHASTON GYNAECOLOGICAL 0% 25.0 -4.2% 0.13% 96% -1.1
70 MANKIND* MANKIND PHARMACEUTICALS LTD. AMLOKIND-AT CARDIAC 12% 24.8 17.1% 0.13% 105% 3.6
71 TORRENT TORRENT PHARMACEUTICALS LTD. NEXPRO RD GASTRO INTESTINAL 5% 24.8 36.3% 0.13% 130% 6.6
72 ABBOTT* NOVO NORDISK INDIA PVT LTD NOVOMIX ANTI DIABETIC 7% 24.6 -10.8% 0.12% 84% -3.0
73 MANKIND* MANKIND PHARMACEUTICALS LTD. UNWANTED KIT GYNAECOLOGICAL 0% 24.6 2.6% 0.12% 102% 0.6
74 PROCTER AND GAMBLE HEALTH PROCTER & GAMBLE HEALTH LTD EVION VITAMINS / MINERALS / NUTRIENTS 5% 24.4 13.5% 0.12% 108% 2.9
75 BLUE CROSS BLUE CROSS LABORATORIES LTD MEFTAL SPAS GASTRO INTESTINAL 5% 24.2 -2.6% 0.12% 93% -0.7
76 SUN* SUN PHARMA LABORATORIES LTD. SOMPRAZ D GASTRO INTESTINAL 5% 23.9 10.7% 0.12% 105% 2.3
77 ABBOTT* ABBOTT HEALTHCARE PVT. LTD STEMETIL GASTRO INTESTINAL 5% 23.8 2.0% 0.12% 97% 0.5
78 CIPLA CIPLA LTD. SEROFLO RESPIRATORY 8% 23.8 3.6% 0.12% 96% 0.8
79 DR. REDDYS DR. REDDYS LABORATORIES LTD ECONORM GASTRO INTESTINAL 5% 23.7 9.8% 0.12% 104% 2.1
80 ZYDUS* ZYDUS CADILA - ZHL LIPAGLYN CARDIAC 12% 23.7 40.4% 0.12% 126% 6.8

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
 Brand Monitor #81 to 100
% MS in G/L % EI against
Incr Gain
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR IPM MS in SG
IPM 19719.8 7.2% 100% 1330.0
81 USV USV PVT LTD ECOSPRIN GOLD CARDIAC 12% 23.5 5.3% 0.12% 94% 1.2
82 FDC FDC LTD. ZIFI ANTI-INFECTIVES 8% 23.4 -7.3% 0.12% 86% -1.8
83 MANKIND* MANKIND PHARMACEUTICALS LTD. MOXIKIND CV ANTI-INFECTIVES 8% 23.1 6.3% 0.12% 99% 1.4
84 SUN* SUN PHARMA LABORATORIES LTD. PANTOCID DSR GASTRO INTESTINAL 5% 23.0 9.7% 0.12% 104% 2.0
85 JB CHEMICALS JB CHEMICALS CILACAR T CARDIAC 12% 22.8 27.2% 0.12% 114% 4.9
86 ALKEM* ALKEM LABORATORIES LTD. PIPZO ANTI-INFECTIVES 8% 22.5 34.2% 0.11% 125% 5.7
87 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MERO ANTI-INFECTIVES 8% 22.2 6.9% 0.11% 99% 1.4
88 MACLEODS MACLEODS PHARMACEUTICALS PVT.LTD MEROMAC ANTI-INFECTIVES 8% 21.9 12.8% 0.11% 105% 2.5
89 PROCTER AND GAMBLE HEALTH PROCTER & GAMBLE HEALTH LTD NEUROBION FORTE VITAMINS / MINERALS / NUTRIENTS 5% 21.6 9.1% 0.11% 104% 1.8
90 GSK GLAXOSMITHKLINE PHARMACEUTICALS LTD. BETNOVATE C DERMA 5% 21.4 11.4% 0.11% 106% 2.2
91 SUN* SUN PHARMA LABORATORIES LTD. RIFAGUT GASTRO INTESTINAL 5% 21.2 11.4% 0.11% 106% 2.2
92 GSK GLAXOSMITHKLINE PHARMACEUTICALS LTD. ELTROXIN HORMONES 8% 21.2 -1.3% 0.11% 92% -0.3
93 USV USV PVT LTD GLYCOMET TRIO ANTI DIABETIC 7% 21.1 3.0% 0.11% 97% 0.6
94 TORRENT TORRENT PHARMACEUTICALS LTD. NIKORAN CARDIAC 12% 20.6 20.8% 0.10% 108% 3.5
95 SANOFI INDIA SANOFI INDIA LTD. ENTEROGERMINA GASTRO INTESTINAL 5% 20.6 19.5% 0.10% 114% 3.4
96 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MONOCEF SB ANTI-INFECTIVES 8% 20.2 12.2% 0.10% 104% 2.2
97 CIPLA CIPLA LTD. IBUGESIC PLUS PAIN / ANALGESICS 7% 20.2 11.4% 0.10% 104% 2.1
98 ARISTO ARISTO PHARMACEUTICALS PVT.LTD MONTAZ ANTI-INFECTIVES 8% 20.0 17.7% 0.10% 109% 3.0
99 CIPLA CIPLA LTD. MONTAIR LC RESPIRATORY 8% 20.0 14.8% 0.10% 107% 2.6
100 ABBOTT* ABBOTT INDIA LTD. CREMAFFIN PLUS GASTRO INTESTINAL 5% 20.0 1.8% 0.10% 97% 0.4

<= 94% 95- 105% >= 106% Notes: EI – Evolution Index, TA – Therapy areas, SG – Super Group
Stars of the Month

Incremental
Gain
Liv 52, Thyronorm, Cilacar, Brilanta, Zostum

%MS Gain

Liv 52, Thyronorm, Brilinta, Vertin, Dexolac 1, Zostum, Alburel,

Zostum, Alburel, Nexpro RD, Lipaglyn, Pipzo

Authored by:

Richa Chaudhary – AVP, BD & Client Engagement

Siddhesh Korgaonkar – Manager, Client Engagement